Persistent cash burn remains a critical concern, with the company reporting a $3.1 million negative free cash flow in 2026Q1 and a cash balance that has dwindled to only $776,000.
| Cash from Operations | -6.4M | -4.99M | -4.97M | -6.5M | -7.04M | -5.02M | -7.55M | -7.08M | -4.4M | -1.34M | 13.98K | -30.11K |
| Operating CF Margin % | - | - | -372.67% | -518.02% | -585.38% | -361.22% | -547.71% | -457.86% | -281.38% | -124.33% | 2.27% | - |
| Operating CF Growth % | -33.49% | -0.38% | 23.61% | 7.57% | -40.06% | 33.42% | -6.59% | -61.05% | -228.14% | -9680.18% | 146.45% | - |
| Net Income | -19.52M | -17.52M | -7.9M | -16.71M | -11.93M | -9.09M | -12.68M | -18.07M | -8.05M | -4.05M | 55.58K | -31.01K |
| Depreciation & Amortization | 675K | 158.83K | 300.47K | 329.95K | 466.28K | 438.78K | 378.48K | 506.74K | 522.84K | 181.64K | 26 | 0 |
| Stock-Based Compensation | 1.05M | 1.82M | 521.51K | 1.18M | 1.11M | 2.11M | 5.49M | 9.21M | 3.09M | 993K | 52.55K | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 109.48K | -1.75M | 0 | 0 | -52.55K | 0 |
| Other Non-Cash Items | 10.98M | 8.87M | 3.34M | 8.73M | 3.11M | 17.31K | 7.55K | 1.39M | 52.97K | 1.32M | 52.55K | 59.67K |
| Working Capital Changes | 310.2K | 1.68M | -1.23M | -35.07K | 206.89K | 1.5M | -856.21K | 1.64M | -12.51K | 213.98K | -94.17K | 900 |
| Change in Receivables | -4.67K | 0 | 130.74K | 0 | -43.77K | -33.77K | 135.22K | -292.64K | -4.13K | 23.91K | -73.41K | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -10.61K | -1.51K | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 282 | 28 | -3.85K | 0 |
| Cash from Investing | 1.19M | 1.05M | -100K | -22.16K | -9.05M | -68.14K | -169.19K | -552.97K | -1.31M | -8.01M | -930.33K | 0 |
| Capital Expenditures | 0 | 0 | 0 | -22.16K | -1.75K | -17.5K | 0 | -377.45K | -113.15K | -929.9K | -334 | 0 |
| CapEx % of Revenue | 0% | - | - | 1.76% | 0.15% | 1.26% | - | 24.41% | 7.24% | 86.3% | 0.05% | - |
| Acquisitions | 0 | - | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 7.29K | -13.45M | 0 | 0 | -9M | -10.33K | 57.97K | -16.32K | -391.51K | -7.16M | -700K | 0 |
| Cash from Financing | 4.72M | 1.4M | 7.64M | 4.83M | 17.26M | 5.17M | 7.66M | 6.15M | 5.04M | 9.5M | 3.79M | 30.3K |
| Debt Issued (Net) | 0 | - | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | 3.51M | 775.5K | 6.36M | 635.39K | 9.74M | 2.86M | 7.26M | 3.96M | 7.03M | 5.15M | 3.63M | 40K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -522.5K | 0 | 0 | 0 |
| Other Financing | 1K | 125.32K | 1.7M | 74.95K | -290.52K | -240.43K | 0 | 0 | -1.49M | 2.85M | 150K | -11.5K |
| Net Change in Cash | -818.43K | -2.55M | 2.57M | -1.71M | 1.18M | 80.96K | -38.31K | -1.49M | -774.75K | 140.84K | 2.78M | 194 |
| Free Cash Flow | -6.4M | -4.99M | -4.97M | -6.53M | -7.04M | -5.04M | -7.55M | -7.46M | -4.51M | -2.27M | 13.65K | -30.11K |
| FCF Margin % | 1828.23% | - | -372.67% | -519.79% | -585.52% | -362.48% | -547.71% | -482.27% | -288.63% | -210.63% | 2.21% | - |
| FCF Growth % | -13.88% | -0.38% | 23.87% | 7.28% | -39.61% | 33.18% | -1.19% | -65.38% | -98.68% | -16727.04% | 145.34% | - |
| FCF per Share | -0.71 | -1.55 | -5.31 | -0.62 | -0.75 | -0.59 | -0.95 | -0.99 | -0.63 | -0.35 | 0.00 | -0.17 |
| FCF Conversion (FCF/Net Income) | 0.33x | 0.27x | 0.63x | 0.39x | 0.59x | 0.55x | 0.60x | 0.39x | 0.57x | 0.39x | 0.25x | 0.97x |
| Interest Paid | 0 | 0 | 1.09M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 21.56K | 0 | 0 |
Imminent liquidity exhaustion
As reported in financial statements, the company consistently records net losses that significantly exceed operating cash outflows, with the 2026Q1 net loss of $4.5 million compared to a $3.1 million cash burn, suggesting that non-cash charges are masking the true severity of the underlying operational deficit.
The recurring gap between net income and operating cash flow indicates that the company is not generating any meaningful cash-based earnings to support its R&D activities. Investors should monitor this divergence, as it suggests that the firm's accounting losses are not merely paper-based but reflect a fundamental inability to convert its business model into a self-sustaining cash-generating engine.
Based on the provided quarterly data, ALBT has maintained a consistently negative free cash flow trajectory, with the most recent 2026Q1 period showing a $3.1 million outflow, confirming that the firm remains entirely dependent on external financing to fund its ongoing clinical development and administrative overhead.
The lack of positive free cash flow margins across the ten-quarter period highlights the absence of a commercialized product or service capable of offsetting the high fixed costs of biotech R&D. This trajectory suggests that the company's cash runway is rapidly approaching a critical exhaustion point, necessitating immediate capital intervention.
According to recent SEC filings, working capital changes have been highly erratic, swinging from a $892.5K inflow in 2025Q4 to an $849.4K outflow in 2026Q1, which indicates a lack of predictable cash management as the firm navigates its transition away from legacy real estate services.
The volatility in working capital suggests that the company may be struggling to manage its payables and receivables effectively during its pivot to a biotech-focused model. This instability in cash conversion cycles warrants further investigation, as it may reflect underlying difficulties in maintaining vendor relationships or collecting on legacy consulting contracts.
As indicated by the historical cash flow statements, the company's reliance on stock-based compensation, which reached $661.3K in 2025Q3, obscures the true cash cost of operations by shifting the burden of talent retention from cash reserves to future shareholder dilution.
While stock-based compensation preserves immediate cash, it represents a significant hidden cost that will ultimately impact existing shareholders through equity dilution. Investors should be wary of this practice, as it appears to be a primary mechanism for managing the firm's limited liquidity in the absence of sustainable operating cash inflows.
Quick answers to the most common questions about buying ALBT stock.
Avalon GloboCare Corp. (ALBT) generated $-5.0M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Avalon GloboCare Corp. (ALBT) reported negative free cash flow of $5.0M in 2025, indicating capital requirements exceeded cash from operations.
Avalon GloboCare Corp. (ALBT) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.